Officials in British Columbia announced on Monday that patients currently taking reference biologics for rheumatological diseases and diabetes will be switched to biosimilar products within 6 months.
Officials in British Columbia announced on Monday that patients currently taking reference biologics for rheumatological diseases and diabetes will be switched to biosimilar products within 6 months.
The new policy will affect the approximately 20,400 British Columbians who have diabetes, ankylosing spondylitis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis. Patients will have 6 months to work with their healthcare providers to transition to a biosimilar from their current reference product, and after November 25, 2019, PharmaCare, the publicly funded national drug coverage program, will no longer provide coverage for reference products other than in exceptional cases (such as when physicians deem individual patients medically unable to transition).
Patients who currently receive reference etanercept (Enbrel) will transition to Samsung Bioepis’ Brenzys (which is also approved in the United States as Eticovo) or Sandoz’s Erelzi. Those taking reference infliximab (Remicade) will be transitioned to Celltrion’s Inflectra or Samsung Bioepis’ and Merck’s Renflexis. Those who currently receive reference insulin glargine (Lantus) will be transitioned to Boehringer Ingelheim and Eli Lilly’s Basaglar.
Officials said that, as an immediate effect of the move toward lower-cost biosimilars, the province was able to make available 2 high-cost innovator drugs: the diabetes therapy empagliflozin (Jardiance) and the psoriatic arthritis drug ixekizumab (Taltz). Access to other products, such as rituximab and certolizumab, will also be expanded on the strength of the $96.6 million (approximately US $71.6 million) over the first 3 years of the program.
In the coming months, officials noted, the approximately 2700 patients receiving biologic treatment for inflammatory bowel disease will also transition their treatment to biosimilars, and more details of this switch will be made available shortly.
In a statement, Biosimilars Canada, a trade group representing biosimilar developers, applauded British Columbia on its decision. “Biosimilar medicines have an important role in supporting health care sustainability and patient care, and Biosimilars Canada congratulates the Government of British Columbia for its Canadian and North American leadership in promoting and expanding the use of biosimilar medicines,” said Michel Robidoux, chair of Biosimilars Canada and president and general manager of Sandoz Canada.
“Switching or transitioning patients from original biologic treatments to their corresponding biosimilar medicines is the responsible choice for those who manage drug budgets, and will help to ensure patient access to essential treatments for years to come,” added Jim Keon, president of Biosimilars Canada.
Biosimilar developer Merck also weighed in; in a statement, Anna Van Acker, president and managing director of Merck Canada Inc, said, “With this announcement, the government of British Columbia has reinforced the important role biosimilars can play in our healthcare system in helping broaden access not only to biologics, but also to innovative medicines overall.”
Commercial Payer Coverage of Biosimilars: Market Share, Pricing, and Policy Shifts
December 4th 2024Researchers observe significant shifts in payer preferences for originator vs biosimilar products from 2017 to 2022, revealing growing payer interest in multiple product options, alongside the increasing market share of biosimilars, which contributed to notable reductions in both average sales prices and wholesale acquisition costs.
Biosimilars Policy Roundup for September 2024—Podcast Edition
October 6th 2024On this episode of Not So Different, we discuss the FDA's approval of a new biosimilar for treating retinal conditions, which took place in September 2024 alongside other major industry developments, including ongoing legal disputes and broader trends in market dynamics and regulatory challenges.
The Rebate War: How Originator Companies Are Fighting Back Against Biosimilars
November 25th 2024Few biologics in the US have multiple biosimilar competitors, but originator biologics respond quickly to competition by increasing rebates and lowering net prices, despite short approval-to-launch timelines for biosimilars.
Boosting Health Care Sustainability: The Role of Biosimilars in Latin America
November 21st 2024Biosimilars could improve access to biologic treatments and health care sustainability in Latin America, but their adoption is hindered by misconceptions, regulatory gaps, and weak pharmacovigilance, requiring targeted education and stronger regulations.